Is this biological real, field-ready, and worth backing?
QBIView is an independent, named diligence verdict on a specific biological product or company, scored against seven readiness layers, with a qualified scientist accountable for the call. Three products, from a CAD $120 self-serve diagnostic to expert-led due diligence.
QBIView · Assessment
sample- Biological Validity82
- Product Integrity74
- Field Translation61
- Regulatory Pathway88
- Commercial Viability55
- Organizational & IP70
- R&D and Governance79
Independent. Named. Accountable for the call.
Why QBIView is different
Most biological claims fail rigorous scrutiny, and many that pass still fall short in the field, after the money is spent. The value is the judgment that separates real from fake, and a name accountable for the call.
The framework
Seven readiness layers, each scored on its own.
Every QBIView assessment scores a biological product or company across the same seven layers. Each is scored independently so weaknesses do not hide behind strengths.
- 01Biological Validity
- 02Product Integrity
- 03Field Translation
- 04Regulatory Pathway
- 05Commercial Viability
- 06Organizational & IP Strength
- 07R&D and Governance
The ladder
Three products. One framework.
01
QBIView Rapid
CAD $120 · self-serve
30-question diagnostic. Instant scored report with Go / Conditional / No-Go signal across seven QBIView dimensions.
Best for: Founders stress-testing their own science, investors triaging a deal, researchers exploring commercialization.
02
QBIView Standard
Consultative · request a quote
Full seven-pillar assessment with confidence intervals and a final scored narrative. Self-serve completion, no advisory.
Best for: Companies preparing for fundraising or partnership, investors doing serious diligence on their own.
03
QBIView Standard + Advisory
Consultative · request a quote
Expert-led version of the Standard assessment. Founder interview, data room review, IP and regulatory analysis, scenarios, QBI Verdict (Go / Conditional / No-Go), and deal-term recommendations. Includes debrief call with Dr. Patrícia Dörr de Quadros.
Best for: Investors making a large commitment; corporate strategics evaluating acquisition or licensing; companies preparing for IC review.
Confidential by default. Not sold. Not published. Not shared without permission.
Not sure which to start with?
We will route you to the right tier.
Tell us the question you are trying to answer and the decision you are facing. We come back with the right QBIView product and a quote.